After A Brief Pause, Injectables Cash Cow Agila Is Back Into Production; Pfizer Expects Shipping To Commence Soon
This article was originally published in PharmAsia News
Executive Summary
Agila, as its name suggests, was agile in correcting deficiencies outlined in an FDA 483 last month and is back on track to supply global customers like Pfizer, GSK and Eli Lilly. But Mylan’s planned buyout of Agila, Strides Arcolab’s cash cow, has hit a snag and been put on hold by India’s finance ministry.
You may also be interested in...
Mylan’s Autor-de-Force Move into Quality “Differentiation” and Sterile Injectables
Mylan is investing heavily to create a competitive advantage based on manufacturing quality – and public policy. The firm’s recruitment of FDA’s Deborah Autor highlights a strategy to spend more on quality while aiming at higher margins, especially in sterile injectables where the company sees an opening after widespread quality breakdowns across the industry.
Form 483 Reply Can Be Ticket To FDA’s Good Side – Attorney
Taking a conciliatory tone and showing a commitment to compliance can help a company avoid further enforcement action after receiving a form 483 from FDA that details “significant” inspectional observations, says food and drug attorney Kate Beardsley.
Drug Shortages Mostly FDA’s Fault, House Oversight Committee Concludes
Report says aggressive enforcement in recent years has forced capacity offline, which led to shortages.